

Supplementary Materials

Biodegradable oxygen-generating microneedle patches for regenerative medicine applications

Lindsay Barnum^{1,2}, Mohamadmahdi Samandari¹, Yasir Suhail^{1,2}, Steven Toro¹, Ashkan Novin¹
Pejman Ghelich^{1,2}, Jacob Quint^{1,2}, Farnooosh Saeedinejad^{1,2}, Kshitiz^{1,2}, Ali Tamayol^{1,2,*}

¹Department of Biomedical Engineering, University of Connecticut Health Center, Farmington, CT 06030, USA

²Department of Biomedical Engineering, University of Connecticut, Storrs, CT 06269, USA

* Corresponding author: A. Tamayol (atamayol@uchc.edu)

Supplementary Figures:




Figure S1: Results of peroxide assay after 5 mM stock solution was treated with dry and fresh 0%(-) and 0%(+) samples.




Figure S2: Average length of microneedles after shrinking through desiccation process.




Figure S3: Swelling ratio of plain GelMA MNA samples over 24 hours.




Figure S4: Distribution of CPO particles in (a) a top view of the backing and (b) a side view of the backing and a needle. Inset image shows zoomed in view of needle tip in focus.




Figure S5: Scanning electron microscopy (SEM) images of a single (a) 0%(-) and (b) 2%(+) microneedle, respectively, showing similar structure.




Figure S6: H&E-stained tissue section showing needle penetration through the dermis. Scale bar represents 500 μm




Figure S7: H_2O_2 present at each time point over 48 hours (a) without catalase and (b) with catalase.




Figure S8: Alternate presentation of Figure 2i and j, showing oxygen release from samples with and without catalase for the four concentrations of CPO studied: (a) 0%, (b) 0.5%, (c) 1%, and (d) 2%.




Figure S9: Drop in oxygen concentration when catalase is introduced to the solution.




Figure S10: Representative Day 3 Live/Dead imaging of HDFs exposed on material samples.

Scale bar represents 500 μ m.




Figure S11: Background testing of most complex treatment sample compared to PrestoBlue control.



Figure S12: Representative image showing 1%(+) MNA placed on the back of wounded mouse.
Scale bar represents 500 μm .




Figure S13: Gene set enrichment analysis showing upregulation in the KEGG pathway for the regulation of actin cytoskeleton.




Figure S14: Cell proliferation related gene ontology sets, and the mean regulation comparing hypoxia control to normoxia control and the 1%(+) treated group in hypoxia to control show a CPO induced reversal in the changes accompanied in hypoxia.




Figure S15: Human umbilical vein endothelial cell response to hypoxia and treatment. (a) PrestoBlue signal after one and three days of culture in 20% and 5% O₂ incubator shows lower viability in hypoxia. (b) PrestoBlue results after three days of culture in 5% O₂ incubator with 0% and 1% CPO material samples. Treatment with 1%(+) sample significantly improves viability over 0%(+) group.

Table S1: Summary of P-values for hydrogen peroxide release.

	(-) Catalase					(+) Catalase				
	2 hour s	5 hour s	8 hour s	24 hours	48 hours	2 hour s	5 hour s	8 hour s	24 hours	48 hours
0% CPO vs. 0.5 % CPO	****	**	***	***	**	ns	ns	ns	ns	ns
0% CPO vs. 1% CPO	***	***	*****	***	**	*	*	*	*	*
0% CPO vs. 2% CPO	*****	*****	*****	*****	**	*	*	*	*	*
0.5% CPO vs. 1 % CPO	ns	ns	ns	ns	*	ns	ns	*	*	*
0.5% CPO vs. 2 % CPO	ns	ns	ns	***	**	ns	*	*	*	*
1% CPO vs. 2% CPO	**	ns	ns	*	**	ns	ns	ns	ns	ns

Table S2: Summary of P-values for oxygen release.

[illegible]

0% CPO vs. 1% CPO	ns	*	*	*	**	**	ns	ns	*	**	ns	**
0% CPO vs. 2% CPO	ns	*	ns	ns	*	ns	*	*	*	***	**	*
0.5% CPO vs. 1% CPO	ns	ns	*	*	*	*	ns	ns	**	*	ns	ns
0.5% CPO vs. 2% CPO	ns	ns	ns	ns	ns	ns	ns	**	*	***	**	*
1% CPO vs. 2% CPO	ns	ns	ns	ns	ns	ns	ns	*	ns	***	**	ns